---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-23-000005"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:11:37.763946+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin reports record Q4 revenues $537.5M (+19% YoY); guides 2023 total rev $2.375-2.5B

## Summary
- Q4 total revenues $537.5M, up 19% YoY; full year $2.096B, up 14%.
- GAAP net loss improved to $0.2M in Q4 from $57.9M loss; full year net income $141.6M.
- VOXZOGO full year revenues $169.1M, up from $5.9M in 2021; 1,264 children treated as of Jan 2023.
- 2023 guidance: total rev $2.375-2.5B, GAAP net income $155-205M, non-GAAP EPS $1.80-2.05.
- ROCTAVIAN 2023 revenue guidance $100-200M; FDA PDUFA date March 31, 2023.

## SEC filing metadata
- accession: 0001048477-23-000005
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000005/0001048477-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000005/bmrn-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-23-000005
- JSON: https://secwatch.observer/filing/0001048477-23-000005.json
- Plain text: https://secwatch.observer/filing/0001048477-23-000005.txt

## Key facts
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC updated its fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).
  - Period: fourth quarter and full year ended December 31, 2022
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 27, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2022. The Company’s press release issued on February 27, 2023 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000005/0001048477-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.